Close Menu

NEW YORK – Immutep this week announced a licensing and collaboration agreement with Laboratory Corporation of America to develop immuno-oncology products or services. Immutep, which develops LAG-3 related immunotherapeutic products, declined to provide additional details about the deal, but its CEO Marc Voight said in an email that it provides the company "the chance to contribute to the immuno-oncology diagnostics field."

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.